(RDCRN 6502) A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation
Description: 

To determine the best clinical response rate of cutaneous sclerosis (skin and/or fascial thickening) after 6 months of initial therapy with eihter Imatinib or Rituximab.

Study Number: 

I 219612

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01309997

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.